Coherus Oncology CHRS
NASDAQ CHRS
$0.99 -0.08 (-7.48%)
At close: Oct 16, 2026 · 4:00 PM EDT

Coherus Oncology (CHRS) Notes Payables (2013 - 2021)

Updated

Coherus Oncology's Notes Payables was $80.98 million in Q3 2021, up 0.5% from the prior quarter.

Analysis

Coherus Oncology (CHRS) Notes Payables (2013 - 2021) Analysis & Trends

At the end of FY2013, Notes Payables at Coherus Oncology came in at $3.09 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,122.91 Bn 1,091.50 Bn 19.71 Bn
2 Johnson & Johnson 615.09 Bn 533.62 Bn 17.26 Bn
3 AbbVie 504.75 Bn 477.86 Bn 12.70 Bn
4 Merck 360.18 Bn 314.55 Bn 12.21 Bn
5 Novartis Ag 292.05 Bn 256.04 Bn 11.24 Bn
6 Astrazeneca 256.09 Bn 229.78 Bn 12.86 Bn
7 Amgen 233.63 Bn 189.02 Bn 7.24 Bn
8 Gilead Sciences 194.49 Bn 168.69 Bn 6.22 Bn
9 Pfizer 168.35 Bn 114.99 Bn 10.94 Bn
10 Coherus Oncology 155.59 Mn -480.55 Mn 10.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 80.98 Mn
Jun 30, 2021 80.61 Mn
Mar 31, 2021 80.24 Mn
Dec 31, 2013 3.09 Mn
API Access

Coherus Oncology Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=CHRS&period=max&api_key=YOUR_API_KEY